Market Overview

UPDATE: J.P. Morgan Reiterates Overweight Rating, Raises PT on Aegerion Pharmaceuticals

Related AEGR
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
Benzinga's Top Upgrades

In a report published Monday, J.P. Morgan & Co. reiterated its Overweight rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and raised its price target from $28.00 to $30.00.

J.P. Morgan noted, “We are reiterating our OW rating on AEGR following FDA approval of Juxtapid (lomitapide) for HoFH, a potentially fatal rare disease characterized by extremely high levels of cholesterol. This event is in line with expectations (we modeled a 95% probability), albeit a few days early (Dec 29th PDUFA). Shares had rallied into this decision so we are not surprised by the initial market reaction. Importantly, the label appears to be favorable with no restrictions on the definition of HoFH (as some bears had postulated) and no surprises with the warnings/REMS. Going forward, we expect the near term outlook for AEGR shares to be driven by 3 key updates, including 1) Juxtapid pricing, which we anticipate at the time of launch in Jan; 2) details of the company's patient tracker (thus providing more context around the market opportunity) at the J.P. Morgan Healthcare conference; and 3) FDA decision on Juxtapid's key competitor Kynamro (mipomersen) where we currently assume approval by the 1/29 PDUFA.”

Aegerion Pharmaceuticals closed on Friday at $25.71.

Latest Ratings for AEGR

Jul 2015JefferiesUpgradesHoldBuy
Jul 2015Guggenheim SecuritiesDowngradesNeutralSell
Oct 2014JefferiesDowngradesBuyHold

View More Analyst Ratings for AEGR
View the Latest Analyst Ratings

Posted-In: J.P. Morgan & Co.Analyst Color Price Target Analyst Ratings


Related Articles (AEGR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters